Catalog No.
PAD12603
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Brolucizumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Beovu.
Specificity
The product is specific for Brolucizumab. This antibody serves as an excellent positive control for Brolucizumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 1531589-13-5
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Brolucizumab is a humanized, single-chain variable fragment to the VEGF-A protein that blocks the effects of VEGF-A, a protein that promotes the growth of blood vessels in the choriocapillaris. Antibodysystem Anti-Brolucizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Brolucizumab.
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review., PMID:40489855
Real-world safety and efficacy of Anti-VEGF treatment in Brazil., PMID:40298749
Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-naïve pachychoroid neovasculopathy., PMID:40259096
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India., PMID:40243051
Three-year visual outcomes after brolucizumab in patients with neovascular age-related macular degeneration., PMID:40229766
Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases., PMID:40206271
Dynamics of Inflammatory Factors in Aqueous Humor During Brolucizumab Treatment for Age-Related Macular Degenerations: A Case Series., PMID:40142183
Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan., PMID:40078048
Budget Impact Analysis of Intravitreal Injections Used to Treat Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in the Dubai Healthcare System., PMID:39978290
Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration., PMID:39962248
Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis., PMID:39859273
Efficacy of switching to brolucizumab for neovascular age-related macular degeneration refractory to faricimab., PMID:39847181
"Triple and Plan" (TriPla) regimen for long lasting new generation intravitreal anti-VEGF., PMID:39763327
Brolucizumab and Platelet Activation and Reactivity., PMID:39760267
Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis., PMID:39746595
[Management of patients with treatment-resistant neovascular age-related macular degeneration]., PMID:39731238
Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study., PMID:39620667
[Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies]., PMID:39569789
Effects on corneal endothelium of intravitreal injection of anti-VEGF drugs., PMID:39560148
First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration., PMID:39496987
Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration., PMID:39455036
Predictive Factors for Submacular Hemorrhage in Age-related Macular Degeneration: A Retrospective Study., PMID:39434578
Occlusive retinal vasculitis and scleritis following brolucizumab treatment: A case report., PMID:39432659
Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration - A systematic review and meta-analysis., PMID:39374696
Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study., PMID:39367347
Incidence of intraocular inflammation and its risk factors in patients treated with brolucizumab: a nationwide cohort study., PMID:39358396
Full thickness macular hole after intravitreal brolucizumab injection in neovascular age-related macular degeneration., PMID:39327941
Effect Modifiers and Risk Factors of Intraocular Inflammation Following Brolucizumab: A Systematic Review and Meta-analysis., PMID:39319615
Impact of vitreomacular interface on intravitreal Brolucizumab efficacy in age-related macular neovascularization., PMID:39279473
Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials., PMID:39261653
Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital., PMID:39257072
[Effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration]., PMID:39254389
MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid., PMID:39182627
Pro Re Nata brolucizumab for early onset and treatment-naïve diabetic macular edema: A prospective study., PMID:39140889
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group., PMID:39078959
Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients., PMID:39064598
Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis., PMID:39043575
Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER., PMID:39033924
Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study., PMID:39004231
Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol., PMID:38995352
Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis., PMID:38915383
Long-term efficacy and safety of brolucizumab in neovascular age-related macular degeneration: A multicentre retrospective real-world study., PMID:38706195
Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report., PMID:38679743
One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment., PMID:38643252
Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration., PMID:38635732
Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab., PMID:38625618
Efficacy of Brolucizumab in Polyp Regression of Treatment-Naive Polypoidal Choroidal Vasculopathy and Its Effect on 1-Year Treatment Outcome., PMID:38584441
Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population., PMID:38564612
Choroidal Thickness and brolucizumab intravitreal injection: Cause or effect of intraocular inflammation?, PMID:38556186
For research use only. Not for human or drug use.
